# US Immunotherapy Drugs market

> US Immunotherapy Drugs Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Autoimmune Disorders, Infectious Diseases, Allergy), By Drug Type (Monoclonal Antibodies, Checkpoint Inhibitors, Vaccines, Cytokines), By Route of Administration (Intravenous, Subcutaneous, Oral) and By End Users (Hospitals, Research Institutions, Pharmaceutical Companies) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.95%
- **2024:** $ 15.05 Billion
- **2025:** $ 16.09 Billion
- **2035:** $ 31.51 Billion
- **Key Players:** Bristol Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Amgen (US), AstraZeneca (GB), Gilead Sciences (US), Regeneron Pharmaceuticals (US), Eli Lilly and Company (US)

**Report ID:** MRFR/Pharma/14739-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-immunotherapy-drugs-market-16267

---

## Market Summary

## **US Immunotherapy Drugs Market Overview**

As per MRFR analysis, the US Immunotherapy Drugs Market Size was estimated at 15.24 (USD Billion) in 2023. The US Immunotherapy Drugs Market Industry is expected to grow from 16.5(USD Billion) in 2024 to 37 (USD Billion) by 2035. The US Immunotherapy Drugs Market CAGR (growth rate) is expected to be around 7.618% during the forecast period (2025 - 2035).

### **Key US Immunotherapy Drugs Market Trends Highlighted**

The US Immunotherapy Drugs Market is witnessing significant trends driven by a combination of innovative research and a growing understanding of cancer treatment. One key market driver is the increasing prevalence of cancer in the US, prompting more patients to seek effective therapeutic options. The National Cancer Institute indicates that millions of Americans are diagnosed with cancer annually, which creates a continuous demand for new immunotherapy drugs that can offer improved outcomes and fewer side effects compared to traditional treatments.

In addition, advancements in biotechnology are allowing for the development of more personalized therapies that target specific patient profiles, further enhancing treatment effectiveness.

Opportunities in the US Immunotherapy Drugs Market are expanding as researchers and companies focus on leveraging combination therapies. This approach involves using immunotherapy in conjunction with other treatment modalities, such as chemotherapy or radiation, to enhance patient responses. Moreover, the growing acceptance of immunotherapy in the treatment of various cancers beyond melanoma, including lung and bladder cancers, highlights an emerging area ripe for development. Recent trends exhibit a surge in clinical trials targeting diverse cancer indications, with many drugs moving swiftly through the regulatory pipeline.

The Food and Drug Administration is actively approving new immunotherapeutic agents, including CAR-T cells and monoclonal antibodies, which showcases a supportive environment for innovation.

Furthermore, the increasing collaboration between pharmaceutical companies and research institutions in the US is likely to accelerate the discovery of novel therapies. Overall, these trends reflect a robust commitment to enhancing cancer treatment options and improving patient care outcomes within the US landscape.

#### Source Primary Research, Secondary Research, MRFR Database and Analyst Review

### **US Immunotherapy Drugs Market Drivers**

#### **Increasing Incidence of Cancer**

The rising incidence of cancer cases in the United States is a primary driver for the growth of the US Immunotherapy Drugs Market Industry. According to the American Cancer Society, about 1.9 million new cancer cases are expected to be diagnosed in 2021, reflecting a consistent increase in the need for effective treatment options. This rising trend emphasizes the urgent requirement for innovative therapies, such as immunotherapy, which harnesses the body's immune system to fight cancer.

Organizations like the National Cancer Institute are continuously reporting on the increasing survival rates and improving therapies in response to this growing demand. As more patients seek advanced treatment modalities due to the escalation in cancer cases, the US Immunotherapy Drugs Market is poised for significant expansion.

#### **Advancements in Research and Development**

The US Immunotherapy Drugs Market Industry is experiencing remarkable growth driven by significant advancements in Research and Development (R&D). The National Institutes of Health has invested exorbitantly in cancer research, with funding exceeding $6 billion annually dedicated to oncology-related R&D. These investments facilitate the innovation of new immunotherapeutic options, including monoclonal antibodies and CAR T-cell therapy, which have shown impressive efficacy in treating various malignancies.

Companies are also increasingly investing in partnership initiatives for collaborative R&D efforts, further driving advancements in treatment options. As therapeutic innovations emerge, the US Immunotherapy Drugs Market is expected to thrive on the back of groundbreaking R&D initiatives.

#### **Regulatory Support and Approval**

Regulatory bodies in the United States, such as the Food and Drug Administration (FDA), are increasingly facilitating the approval processes for immunotherapy drugs. The FDA has implemented expedited programs like the Breakthrough Therapy designation to accelerate the development and review of medications that can offer significant benefits over existing therapies. In recent years, multiple immunotherapy drugs received rapid approvals, showcasing the agency's commitment to providing patients with timely access to alternative treatments.

This supportive regulatory environment encourages pharmaceutical companies to invest more in the US Immunotherapy Drugs Market, fuelling its growth.

#### **Rising Awareness and Acceptance of Immunotherapies**

There is an increasing awareness and acceptance of immunotherapy treatments among healthcare professionals and patients in the United States. Initiatives from organizations such as the American Society of Clinical Oncology are designed to educate both physicians and patients about the potential benefits of immunotherapies. Reports indicate that an increasing number of clinical trials focusing on immunotherapy are being conducted, signifying a growing confidence in these novel approaches to cancer treatment.

As more physicians adopt immunotherapy as a treatment option and more patients request information on these therapies, the US Immunotherapy Drugs Market is poised for steady growth.

## **US Immunotherapy Drugs Market Segment Insights**

### **Immunotherapy Drugs Market Therapeutic Area Insights**

The US Immunotherapy Drugs Market has shown substantial growth and relevance within the Therapeutic Area segment, positioning itself as a critical player in the healthcare landscape. With the market valued at 16.5 Billion USD in 2024 and expected to reach 37.0 Billion USD by 2035, the significance of immunotherapy in treating various diseases cannot be overstated. Within this segment, Oncology stands out as a dominant area, driven by the increasing prevalence of cancer and ongoing innovations in cancer treatments.

This therapeutic approach not only targets tumors more effectively but also leverages the body's immune system to restore its natural defenses, thus presenting a revolutionary shift in cancer care.

Autoimmune Disorders represent another vital area where immunotherapy has become integral, providing new treatment avenues for patients suffering from conditions such as rheumatoid arthritis and lupus. The rise in autoimmune diseases in the US is influencing the rate of Research and Development investments, leading to more diverse treatment options that improve patients' quality of life and overall health outcomes. Infectious Diseases are yet another crucial segment, particularly emerging infections and chronic viral illnesses, which underscore the demand for advanced immunotherapeutic strategies. This is reflective of broader public health efforts to enhance immune responses against various pathogens.

Allergy treatments also play a significant part in this market, as they address increasing rates of allergic reactions and sensitivities in the US population. The need for effective therapeutic solutions in this area highlights the growing emphasis on personalized medicine and tailored treatment plans that cater to individual patient needs. Overall, the US Immunotherapy Drugs Market segmentation across these therapeutic areas reflects a robust framework that underpins innovative approaches to healthcare, driven by broadening clinical applications and the continual emergence of new scientific insights.

This dynamic landscape presents a multitude of growth opportunities and latent challenges as stakeholders navigate the complexities of the healthcare environment in a nation increasingly focused on improving patient outcomes through targeted therapies.

#### Source Primary Research, Secondary Research, MRFR Database and Analyst Review

### **Immunotherapy Drugs Market Drug Type Insights**

The Drug Type segment of the US Immunotherapy Drugs Market showcases a diverse and evolving landscape with key focus on various therapeutic approaches. Monoclonal Antibodies have emerged as a significant force due to their ability to target specific cells, offering precise treatment alternatives for conditions like cancer and autoimmune diseases. Checkpoint Inhibitors, known for their role in enhancing the immune response against tumors, have gained prominence in oncology, contributing to numerous successful clinical outcomes. Vaccines are pivotal in preventive strategies against infectious diseases and cancer, driving innovation and development in vaccine research.

Cytokines, as immune system modulators, play a crucial role in enhancing immune responses and are being explored for their potential in treating various conditions. Collectively, these categories highlight significant advancements in immunotherapy, addressing critical healthcare needs and driving the market growth in the US Immunotherapy Drugs Market. As research and development efforts advance, these drug types are anticipated to continue leading in efficacy and delivering optimized therapeutic benefits.

### **Immunotherapy Drugs Market Route of Administration Insights**

The Route of Administration segment within the US Immunotherapy Drugs Market plays a crucial role in determining the effectiveness and patient compliance of therapies. Among the various administration routes, Intravenous delivery is often favored for its rapid onset of action and ability to achieve higher concentrations of the drug directly into the bloodstream, making it particularly vital for acute treatments. Meanwhile, Subcutaneous administration has gained traction due to its ease of use and convenience for self-administration, which enhances patient adherence to treatment regimens.

Oral immunotherapy options, although less prevalent, present significant opportunities for market growth by providing an alternative that could improve patient comfort and compliance. The dominant presence of these administration methods reflects the ongoing trends towards patient-centric care and the continuous innovation within drug delivery systems to address specific therapeutic needs. The US Immunotherapy Drugs Market illustrates how variations in the Route of Administration contribute to an array of options that cater to diverse patient populations and disease conditions, emphasizing the importance of tailored treatment approaches in improving overall healthcare outcomes.

### **Immunotherapy Drugs Market End User Insights**

The US Immunotherapy Drugs Market exhibits diverse dynamics across its End User landscape, encompassing Hospitals, Research Institutions, and Pharmaceutical Companies. Hospitals play a crucial role in delivering immunotherapy treatments, providing advanced care and specialized services to a growing patient demographic, particularly those with cancer and autoimmune diseases. This segment is vital as it ensures access to innovative therapies and ongoing patient management.

Research Institutions are pivotal in driving the US Immunotherapy Drugs Market forward, spearheading clinical trials and studies that enhance understanding of immunotherapy's efficacy and safety. Their contributions not only foster product innovation but also facilitate regulatory approvals, ultimately shaping future treatment protocols. Pharmaceutical Companies significantly influence this market segment through research and development efforts, developing new therapies, and optimizing existing treatments.

Their commitment to innovation and collaboration with healthcare providers and institutions underscores their importance in bringing effective immunotherapy drugs to the market, aligning with national health objectives to improve patient outcomes. The interconnectivity of these segments underpins the overall growth and advancement of the US Immunotherapy Drugs Market, addressing the evolving healthcare needs of the population.

## **US Immunotherapy Drugs Market Key Players and Competitive Insights**

The US Immunotherapy Drugs Market is characterized by rapid innovation and fierce competition among several key players. This dynamic market is driven by the increasing prevalence of cancer and autoimmune diseases, which has led to heightened demand for effective treatment options. The competitive landscape is marked by significant investments in research and development, strategic collaborations, and a focus on technology integration to enhance therapeutic outcomes. Regulatory approvals, patent expirations, and pricing strategies are pivotal factors influencing companies' market strategies, as they vie for enhanced market share in this lucrative field.

As a result, firms are compelled to adopt aggressive marketing and branding tactics, while navigating the complexities of compliance and health policy changes, ultimately shaping their competitive position within the market.

Genentech, a leader in the US Immunotherapy Drugs Market, possesses several strengths that enhance its competitive standing. The company is renowned for its pioneering research and development capabilities, which have led to the successful launch of numerous immunotherapy products that address critical unmet medical needs. Genentech’s robust pipeline reflects its commitment to advancing innovative treatments for cancer and other diseases, bolstering its reputation for reliability in delivering effective therapies.

Furthermore, Genentech has established a strong market presence through strategic collaborations and partnerships with healthcare providers and organizations, ensuring that its offerings reach a broad patient population. The company’s dedication to patient-centric solutions and its active involvement in clinical trials play a crucial role in solidifying its position as a trusted name in the immunotherapy domain.

Bristol Myers Squibb is another formidable contender in the US Immunotherapy Drugs Market, recognized for its extensive range of cancer therapies that leverage immune system mechanisms. The company's key products include leading immuno-oncology agents that have achieved significant market penetration, underscoring its commitment to improving patient outcomes. Bristol Myers Squibb's strengths are complemented by strategic mergers and acquisitions that have bolstered its product portfolio and expanded its technological capabilities.

Through these initiatives, the company has not only enhanced its presence in the market but also reinforced its alignment with evolving treatment paradigms in oncology. Bristol Myers Squibb's sustained focus on innovative research and the development of novel therapeutic approaches, coupled with its proactive engagement in partnerships, solidifies its position as a key player in the US Immunotherapy Drugs Market, enabling the firm to tackle future challenges effectively and fulfill the increasing demand for advanced treatment options.

### **Key Companies in the US Immunotherapy Drugs Market Include**

## **US Immunotherapy Drugs Market Industry Developments**

The US [Immunotherapy Drugs](../../../reports/immunotherapy-drugs-market-7399) Market has seen significant developments recently with companies such as Bristol Myers Squibb and Merck continuing to innovate and expand their treatment options for cancer and autoimmune diseases. In September 2023, Gilead Sciences announced promising data from its Phase 2 trial of an immunotherapy that targets specific cancer types, showcasing its potential to enhance patient outcomes. Additionally, AstraZeneca reported advancements in combination therapies, significantly impacting survival rates among patients with advanced stage cancer, indicating strong market growth in efficacious treatments.

In terms of mergers and acquisitions, Genentech and Novartis are notable; Genentech completed the acquisition of a smaller biotech firm focused on niche immunotherapies in June 2023 to bolster its product pipeline. Also, Regeneron Pharmaceuticals strengthened its market position with an acquisition in August 2023 that expanded its immunotherapy offerings and Research and Development capabilities. Over the past few years, the market has seen substantial investment and growth, particularly in 2022, highlighting the increasing importance of immunotherapies as an integral part of cancer treatment options in the US healthcare landscape.

## **US Immunotherapy Drugs Market Segmentation Insights**

### **Immunotherapy Drugs Market Therapeutic Area Outlook**

### **Immunotherapy Drugs Market Drug Type Outlook**

### **Immunotherapy Drugs Market Route of Administration Outlook**

### **Immunotherapy Drugs Market End User Outlook**

## Market Drivers

### Increasing Cancer Incidence

The rising incidence of cancer in the US is a primary driver for the immunotherapy drugs market. According to the American Cancer Society, approximately 1.9 million new cancer cases are expected to be diagnosed in 2025. This alarming trend necessitates innovative treatment options, with immunotherapy emerging as a promising solution. The effectiveness of immunotherapy in treating various cancers, including melanoma and lung cancer, has garnered significant attention. As healthcare providers seek to improve patient outcomes, the demand for immunotherapy drugs is likely to increase. Furthermore, the growing awareness among patients and healthcare professionals about the benefits of immunotherapy could further propel market growth. The immunotherapy drugs market is thus positioned to expand as it addresses the urgent need for effective cancer treatments.

### Regulatory Support and Approvals

Regulatory support plays a crucial role in shaping the immunotherapy drugs market. The US Food and Drug Administration (FDA) has streamlined the approval process for immunotherapy drugs, recognizing their potential to treat various cancers. In recent years, the FDA has granted accelerated approvals for several immunotherapeutic agents, which has encouraged pharmaceutical companies to invest in this area. As of 2025, the number of approved immunotherapy drugs has increased significantly, with over 30 agents currently available on the market. This regulatory environment fosters innovation and encourages the development of new therapies. The immunotherapy drugs market is likely to continue thriving as regulatory bodies remain supportive of advancements that can improve patient outcomes.

### Growing Investment in Biotechnology

The increasing investment in biotechnology is a significant driver for the immunotherapy drugs market. Venture capital funding for biotech companies has surged, with estimates suggesting that investments reached approximately $30 billion in 2025. This influx of capital is facilitating the development of cutting-edge immunotherapy treatments. Biotech firms are focusing on harnessing the immune system to combat cancer, leading to the emergence of novel therapies. The immunotherapy drugs market stands to benefit from this trend, as innovative products are developed and brought to market. Furthermore, partnerships between biotech companies and larger pharmaceutical firms are likely to enhance research capabilities and accelerate the commercialization of new therapies.

### Rising Patient Awareness and Demand

Patient awareness regarding immunotherapy and its benefits is on the rise, significantly impacting the immunotherapy drugs market. Educational campaigns and advocacy groups are actively informing patients about the advantages of immunotherapy in cancer treatment. As of 2025, surveys indicate that nearly 70% of cancer patients are aware of immunotherapy options. This heightened awareness is likely to lead to increased demand for these therapies, as patients seek out the most effective treatment options available. The immunotherapy drugs market is expected to grow as healthcare providers respond to this demand by offering more immunotherapeutic solutions. Additionally, the shift towards patient-centered care is further driving the adoption of immunotherapy.

### Advancements in Research and Development

Ongoing advancements in research and development (R&D) are significantly influencing the immunotherapy drugs market. The US is home to numerous leading pharmaceutical companies and research institutions that are investing heavily in R&D. In 2025, it is estimated that R&D spending in the biopharmaceutical sector will exceed $100 billion. This investment is likely to lead to the discovery of novel immunotherapeutic agents and combination therapies that enhance treatment efficacy. Additionally, breakthroughs in understanding the immune system and tumor microenvironment are paving the way for innovative therapies. The immunotherapy drugs market is expected to benefit from these advancements, as new products enter the market and existing therapies are improved, ultimately providing patients with more effective treatment options.

## Future Outlook

The [Immunotherapy Drugs market](https://www.marketresearchfuture.com/reports/immunotherapy-drugs-market-7399) is projected to grow at a 6.95% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increasing cancer prevalence, and enhanced R&D investments.

**New opportunities:**

- Development of combination therapies to enhance efficacy and patient outcomes. Expansion into emerging markets with tailored immunotherapy solutions. Investment in [digital health](https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636) technologies for patient monitoring and engagement.

By 2035, the immunotherapy drugs market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Therapeutic Area: Oncology (Largest) vs. Autoimmune Disorders (Fastest-Growing)

In the US immunotherapy drugs market, the Oncology segment holds a significant share, reflecting its established role in cancer treatment. This segment has benefited from innovations and new product approvals that enhance therapeutic options for various cancer types. Following closely, the Autoimmune Disorders segment is experiencing rapid growth as advances in understanding these conditions lead to the development of targeted therapies that improve patient outcomes. The growth trends in these segments are driven by increasing prevalence rates and a shift towards personalized medicine. Ongoing research and development efforts are focusing on enhancing the efficacy of treatments while minimizing side effects. The surge in demand for immunotherapies in both Oncology and Autoimmune Disorders indicates a robust future market potential, highlighted by investments and collaborations among pharmaceutical companies.

Oncology: Dominant vs. Autoimmune Disorders: Emerging

The Oncology segment is recognized as the dominant player in the US immunotherapy drugs market, attributed to its broad range of applications including various malignancies such as lung, breast, and melanoma. Innovations such as checkpoint inhibitors and CAR T-cell therapies have revolutionized treatment paradigms, resulting in improved survival rates and broad acceptance among healthcare providers. In contrast, the Autoimmune Disorders segment is emerging with high growth potential, driven by increasing awareness and diagnosis of conditions like rheumatoid arthritis and multiple sclerosis. The development of biologics and targeted therapies tailored for these disorders is gaining traction, leading to significant advancements in patient care and a positive outlook for market expansion.

### By Drug Type: Monoclonal Antibodies (Largest) vs. Checkpoint Inhibitors (Fastest-Growing)

The distribution of market share in the drug type segment reflects a significant presence of Monoclonal Antibodies, which dominate the market due to their established efficacy and widespread use in treating various cancers. In contrast, Checkpoint Inhibitors are rapidly gaining ground, appealing to a growing population of patients seeking advanced therapies. The variations in share highlight the evolving landscape, where traditional therapeutic approaches coexist with innovative strategies aimed at enhancing patient outcomes. Growth trends within this segment are driven by continuous advancements in biologics, coupled with increased investment in research and development. The push for [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) is compelling pharmaceutical companies to refine their product offerings, especially in Checkpoint Inhibitors, which are recognized for their transformative impact on treatment paradigms. These trends point to a robust pipeline that promises to further diversify the options available within the market.

Monoclonal Antibodies (Dominant) vs. Checkpoint Inhibitors (Emerging)

Monoclonal Antibodies represent a dominant force in the drug type segment, known for their specificity and effectiveness in targeting cancer cells. They are widely prescribed for various indications, including melanoma, lymphoma, and breast cancer, offering a well-established treatment pathway for oncologists. Their long history in clinical use has cultivated a strong trust among healthcare providers and patients alike. Conversely, Checkpoint Inhibitors are emerging as a revolutionary treatment option, unlocking the immune system's potential to combat tumors. This innovative approach allows for enhanced durability in treatment effects and is particularly attractive in cases where conventional therapies have failed, positioning them as a key area for future growth within the US immunotherapy drugs market.

### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

The market share distribution among the route of administration segment for immunotherapy drugs reveals that intravenous administration holds the largest share, owing to its established efficacy and rapid onset of action. This method is widely preferred for various treatments, especially when high doses are required. In contrast, subcutaneous administration is gaining traction as an alternative, particularly within specific patient populations that favor less invasive options, capturing a growing segment of the market. Growth trends in the route of administration segment are being driven by evolving patient preferences, technological advancements, and ongoing research into novel drug formulations. Intravenous administration is likely to maintain its dominance, while subcutaneous administration emerges as a favored choice for outpatient treatments, largely influenced by convenience and the potential for self-administration. This shift reflects a broader trend towards patient-centered care and improved quality of life for patients undergoing immunotherapy.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration is characterized by the direct delivery of immunotherapy drugs into the bloodstream, which allows for immediate therapeutic effects and is particularly beneficial for patients requiring aggressive treatment regimens. Its established safety profile and the ability to administer high volumes make it the dominant method in the market. On the other hand, subcutaneous administration represents an emerging trend, where drugs are injected into the tissue layer between the skin and the muscle. This method is increasingly appealing as it reduces the need for hospital visits, aligns with patient convenience, and supports the growing preference for at-home treatment options, thereby enhancing patient adherence and satisfaction.

### By End User: Hospitals (Largest) vs. Research Institutions (Fastest-Growing)

In the US immunotherapy drugs market, hospitals hold the largest market share, leveraging their vast resources and patient access to implement immunotherapy treatments effectively. This segment is crucial as hospitals not only administer these therapies but also play a significant role in the clinical trials that help advance immunotherapy options. Research institutions follow as an emerging force, energizing the landscape through innovative studies and trials that drive the development of new therapies. The growth trends in this segment are particularly influenced by the rising incidence of diseases treatable by immunotherapy, coupled with increasing investment in research and development. Hospitals are continuously optimizing treatment protocols, while research institutions are experiencing rapid growth as they expand their capabilities and collaboration with pharmaceutical companies. This synergy enhances the development pipeline and creates a robust environment for innovation in immunotherapy.

Hospitals (Dominant) vs. Research Institutions (Emerging)

Hospitals serve as the dominant players in the US immunotherapy drugs market, equipped with the infrastructure to deliver cutting-edge treatments directly to patients. They are at the forefront of adopting immunotherapy protocols and are instrumental in collecting patient data that informs future treatment options. In contrast, research institutions are emerging as vital contributors, driving innovation through advanced research and clinical trials. Their role is crucial in characterizing new drug mechanisms and identifying novel therapeutic targets, facilitating collaboration with pharmaceutical companies to bring innovative therapies into hospitals. The interplay between these two segments fosters an ecosystem where patient care and research advancements work hand in hand, promoting faster adoption and improved outcomes in immunotherapy practices.

## Competitive Benchmarking

The immunotherapy drugs market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on personalized medicine. Major players such as Bristol Myers Squibb (US), Merck & Co (US), and Roche (CH) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their product offerings. Bristol Myers Squibb (US) emphasizes its commitment to advancing cancer treatment through innovative therapies, while Merck & Co (US) focuses on expanding its immunotherapy portfolio, particularly in combination therapies. Roche (CH) is strategically positioned with its robust pipeline and emphasis on precision medicine, which collectively shapes a competitive environment that is increasingly focused on patient-centric solutions. Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The competitive structure appears moderately fragmented, with several key players exerting substantial influence. This fragmentation allows for a diverse range of therapeutic options, yet the collective strength of major companies facilitates significant advancements in research and development, ultimately benefiting patient outcomes. In October 2025, Merck & Co (US) announced a strategic collaboration with a leading biotechnology firm to develop next-generation immunotherapies. This partnership is expected to enhance Merck's capabilities in harnessing novel biomarkers for patient selection, potentially leading to more effective treatment regimens. Such collaborations indicate a trend towards integrating cutting-edge technology with traditional therapeutic approaches, thereby enhancing the overall efficacy of immunotherapy. In September 2025, Bristol Myers Squibb (US) launched a new clinical trial aimed at evaluating the efficacy of its latest immunotherapy in combination with targeted therapies for lung cancer. This initiative underscores the company's commitment to exploring innovative treatment combinations that may improve patient outcomes. The trial's results could significantly influence treatment protocols and establish new standards in lung cancer care. In August 2025, Roche (CH) expanded its manufacturing capabilities in the US to support the growing demand for its immunotherapy products. This expansion not only enhances Roche's production capacity but also reflects a strategic move to ensure supply chain reliability amidst increasing market competition. Such investments are crucial for maintaining a competitive edge in a rapidly evolving market. As of November 2025, current trends in the immunotherapy drugs market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, thereby fostering a more resilient and responsive market environment.

## Recent News & Developments

The US [Immunotherapy Drugs](../../../reports/immunotherapy-drugs-market-7399) Market has seen significant developments recently with companies such as Bristol Myers Squibb and Merck continuing to innovate and expand their treatment options for cancer and autoimmune diseases. In September 2023, Gilead Sciences announced promising data from its Phase 2 trial of an immunotherapy that targets specific cancer types, showcasing its potential to enhance patient outcomes. Additionally, AstraZeneca reported advancements in combination therapies, significantly impacting survival rates among patients with advanced stage cancer, indicating strong market growth in efficacious treatments.

In terms of mergers and acquisitions, Genentech and Novartis are notable; Genentech completed the acquisition of a smaller biotech firm focused on niche immunotherapies in June 2023 to bolster its product pipeline. Also, Regeneron Pharmaceuticals strengthened its market position with an acquisition in August 2023 that expanded its immunotherapy offerings and Research and Development capabilities. Over the past few years, the market has seen substantial investment and growth, particularly in 2022, highlighting the increasing importance of immunotherapies as an integral part of cancer treatment options in the US healthcare landscape.

## Report Scope

| MARKET SIZE 2024 | 15.05(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 16.09(USD Billion) |
| MARKET SIZE 2035 | 31.51(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.95% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Amgen (US), AstraZeneca (GB), Gilead Sciences (US), Regeneron Pharmaceuticals (US), Eli Lilly and Company (US) |
| Segments Covered | Therapeutic Area, Drug Type, Route of Administration, End User |
| Key Market Opportunities | Advancements in personalized medicine enhance treatment efficacy in the immunotherapy drugs market. |
| Key Market Dynamics | Rising demand for personalized therapies drives innovation and competition in the immunotherapy drugs market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US immunotherapy drugs market in 2024?**
A: The market valuation of the US immunotherapy drugs market was $15.05 Billion in 2024.

**Q: What is the projected market valuation for the US immunotherapy drugs market by 2035?**
A: The projected market valuation for the US immunotherapy drugs market is $31.51 Billion by 2035.

**Q: What is the expected CAGR for the US immunotherapy drugs market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US immunotherapy drugs market during the forecast period 2025 - 2035 is 6.95%.

**Q: Which therapeutic area is expected to dominate the US immunotherapy drugs market?**
A: The oncology segment is expected to dominate the US immunotherapy drugs market, with a valuation projected to grow from $8.0 Billion to $16.5 Billion.

**Q: What are the key drug types in the US immunotherapy drugs market?**
A: Key drug types in the US immunotherapy drugs market include monoclonal antibodies, checkpoint inhibitors, vaccines, and cytokines.

**Q: How much is the intravenous route of administration expected to grow in the US immunotherapy drugs market?**
A: The intravenous route of administration is expected to grow from $6.02 Billion to $12.45 Billion in the US immunotherapy drugs market.

**Q: Which end user segment is projected to have the highest valuation in the US immunotherapy drugs market?**
A: Pharmaceutical companies are projected to have the highest valuation in the US immunotherapy drugs market, growing from $7.02 Billion to $15.11 Billion.

**Q: Who are the leading companies in the US immunotherapy drugs market?**
A: Leading companies in the US immunotherapy drugs market include Bristol Myers Squibb, Merck & Co, Roche, Novartis, and Amgen.

**Q: What is the expected growth for the autoimmune disorders segment in the US immunotherapy drugs market?**
A: The autoimmune disorders segment is expected to grow from $3.0 Billion to $6.5 Billion in the US immunotherapy drugs market.

**Q: What is the projected growth for the vaccines segment in the US immunotherapy drugs market?**
A: The vaccines segment is projected to grow from $3.0 Billion to $6.0 Billion in the US immunotherapy drugs market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-immunotherapy-drugs-market-16267*